MicroRNA expression as risk biomarker of breast cancer metastasis: A pilot retrospective case-cohort study

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Marino, Augusto L F ^a   Evangelista, Adriane F ^a   Vieira, René A C ^b   Macedo, Taciane ^a   Kerr, Ligia M ^b   Abrahão Machado, Lucas F ^b   Longatto Filho, Adhemar ^a,d,e,f   Silveira, Henrique C S ^a   Marques, Marcia M C ^a,c  

^a BARRETOS CANCER HOSPITAL   (Brazil)

^b BARRETOS CANCER HOSPITAL   (Brazil)

^c Barretos School of Health Sciences   (Brazil)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSITY OF MINHO   (Portugal)

^f UNIVERSITY OF MINHO   (Portugal)

Author keywords

Biomarkers; Breast cancer; Metastasis; MicroRNAs; Molecular profile; Retrospective study

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 183; MICRORNA 21; MICRORNA 494; MOLECULAR MARKER; UNCLASSIFIED DRUG; MIRN183 MICRORNA, HUMAN; MIRN21 MICRORNA, HUMAN; MIRN494 MICRORNA, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CASE STUDY; CELL MOTILITY; CLINICAL ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DISTANT METASTASIS; FOLLOW UP; GENE EXPRESSION; HUMAN; METASTASIS POTENTIAL; PATIENT CODING; PILOT STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; UPREGULATION; BREAST TUMOR; DNA MICROARRAY; FEMALE; GENETICS; METASTASIS; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PILOT PROJECTS; PROGNOSIS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84910039146     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-739     Document Type: Article

References (55)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90. 10.3322/caac.20107, 21296855.
2. Sobin LH, Gospodarowicz M, Wittekind C. TNM Classification of Malignant Tumours 2010, Oxford: Wiley-Blackwell, 7.
3. Sandhu R, Parker JS, Jones WD, Livasy CA, Coleman WB. Microarray-based gene expression profiling for molecular classification of breast cancer and identification of new targets for therapy. Lab Med 2010, 41:364-372.
4. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
5. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR. MicroRNA expression profiles classify human cancers. Nature 2005, 435:834-838. 10.1038/nature03702, 15944708.
6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297. 10.1016/S0092-8674(04)00045-5, 14744438.
7. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, Ju J. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007, 13:1668-1674. 10.1261/rna.642907, 1986820, 17698639.
8. Li J, Smyth P, Flavin R, Cahill S, Denning K, Aherne S, Guenther SM, O'Leary JJ, Sheils O. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol 2007, 7:36. 10.1186/1472-6750-7-36, 1914054, 17603869.
9. Carleton M, Cleary MA, Linsley PS. MicroRNAs and cell cycle regulation. Cell Cycle 2007, 6:2127-2132. 10.4161/cc.6.17.4641, 17786041.
10. Boehm M, Slack FJ. MicroRNA control of lifespan and metabolism. Cell Cycle 2006, 5:837-840. 10.4161/cc.5.8.2688, 16627994.
11. Baltimore D, Boldin MP, O'Connell RM, Rao DS, Taganov KD. MicroRNAs: new regulators of immune cell development and function. Nat Immunol 2008, 9:839-845. 10.1038/ni.f.209, 18645592.
12. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med 2009, 60:167-179. 10.1146/annurev.med.59.053006.104707, 19630570.
13. Iorio MV, Ferracin M, Liu C-G, Veronese A, Spizzo R, Sabbioni S, Magri E, Pedriali M, Fabbri M, Campiglio M, Ménard S, Palazzo JP, Rosenberg A, Musiani P, Volinia S, Nenci I, Calin GA, Querzoli P, Negrini M, Croce CM. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005, 65:7065-7070. 10.1158/0008-5472.CAN-05-1783, 16103053.
14. Blenkiron C, Goldstein LD, Thorne NP, Spiteri I, Chin S-F, Dunning MJ, Barbosa-Morais NL, Teschendorff AE, Green AR, Ellis IO, Tavaré S, Caldas C, Miska EA. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 2007, 8:R214. 10.1186/gb-2007-8-10-r214, 2246288, 17922911.
15. Valastyan S. Roles of microRNAs and other non-coding RNAs in breast cancer metastasis. J Mammary Gland Biol Neoplasia 2012, 17:23-32. 10.1007/s10911-012-9241-9, 22293951.
16. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008, 14:818-829. 10.1016/j.devcel.2008.05.009, 18539112.
17. Sreekumar R, Sayan BS, Mirnezami AH, Sayan AE. MicroRNA control of invasion and metastasis pathways. Front Genet 2011, 2:58. 3268611, 22303353.
18. Lowery AJ, Miller N, Dwyer RM, Kerin MJ. Dysregulated miR-183 inhibits migration in breast cancer cells. BMC Cancer 2010, 10:502. 10.1186/1471-2407-10-502, 2955037, 20858276.
19. Luo D, Wilson JM, Harvel N, Liu J, Pei L, Huang S, Hawthorn L, Shi H. A systematic evaluation of miRNA:mRNA interactions involved in the migration and invasion of breast cancer cells. J Transl Med 2013, 11:57. 10.1186/1479-5876-11-57, 3599769, 23497265.
20. Zhang Q-H, Sun H-M, Zheng R-Z, Li Y-C, Zhang Q, Cheng P, Tang Z-H, Huang F. Meta-analysis of microRNA-183 family expression in human cancer studies comparing cancer tissues with noncancerous tissues. Gene 2013, 527:26-32. 10.1016/j.gene.2013.06.006, 23791657.
21. Rundle AG, Vineis P, Ahsan H. Design options for molecular epidemiology research within cohort studies. Cancer Epidemiol Biomarkers Prev 2005, 14:1899-1907. 10.1158/1055-9965.EPI-04-0860, 16103435.
22. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MCU, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502. 10.1001/jama.295.21.2492, 16757721.
23. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101:736-750. 10.1093/jnci/djp082, 2684553, 19436038.
24. The R Project for Statistical Computing. [http://www.r-project.org].
25. Bengtsson H, Hössjer O. Methodological study of affine transformations of gene expression data with proposed robust non-parametric multi-dimensional normalization method. BMC Bioinformatics 2006, 7:100. 10.1186/1471-2105-7-100, 1534066, 16509971.
26. Hong F, Breitling R, McEntee CW, Wittner BS, Nemhauser JL, Chory J. RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics 2006, 22:2825-2827. 10.1093/bioinformatics/btl476, 16982708.
27. Park SH, Goo JM, Jo C-H. Receiver operating characteristic (ROC) curve: practical review for radiologists. Korean J Radiol 2004, 5:11-18. 10.3348/kjr.2004.5.1.11, 2698108, 15064554.
28. Sing T, Sander O, Beerenwinkel N, Lengauer T. ROCR: visualizing classifier performance in R. Bioinformatics 2005, 21:3940-3941. 10.1093/bioinformatics/bti623, 16096348.
29. gplots: Various R programming tools for plotting data. [http://cran.r-project.org/web/packages/gplots/index.html].
30. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45. 10.1093/nar/29.9.e45, 55695, 11328886.
31. Therneau T, Lumley T. R: Survival analysis, including penalised likelihood. [http://stat.ethz.ch/R-manual/R-patched/library/survival/html/00Index.html].
32. mirDIP: microRNA Data Integration Portal. [http://ophid.utoronto.ca/mirDIP/].
33. DAVID Functional Annotation Bioinformatics Microarray Analysis. [http://david.abcc.ncifcrf.gov].
34. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 2008, 4:44-57.
35. Hall JS, Taylor J, Valentine HR, Irlam JJ, Eustace A, Hoskin PJ, Miller CJ, West CML. Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation. Br J Cancer 2012, 107:684-694. 10.1038/bjc.2012.294, 3419950, 22805332.
36. Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011, 378:1812-1823. 10.1016/S0140-6736(11)61539-0, 22098854.
37. Cobleigh MA, Tabesh B, Bitterman P, Baker J, Cronin M, Liu M-L, Borchik R, Mosquera J-M, Walker MG, Shak S. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin Cancer Res 2005, 11(24 Pt 1):8623-8631.
38. Veer LJ VT, Dai H, van de Vijver MJ, He YD, Hart AAM, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536. 10.1038/415530a, 11823860.
39. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn H-J. Panel members: Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011, 22:1736-1747. 10.1093/annonc/mdr304, 3144634, 21709140.
40. Asangani IA, Rasheed SAK, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008, 27:2128-2136. 10.1038/sj.onc.1210856, 17968323.
41. Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, Li Y. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 2008, 27:4373-4379. 10.1038/onc.2008.72, 18372920.
42. Watanabe S, Ueda Y, Akaboshi S, Hino Y, Sekita Y, Nakao M. HMGA2 maintains oncogenic RAS-induced epithelial-mesenchymal transition in human pancreatic cancer cells. Am J Pathol 2009, 174:854-868. 10.2353/ajpath.2009.080523, 2665746, 19179606.
43. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 2007, 315:1576-1579. 10.1126/science.1137999, 2556962, 17322030.
44. Liu Y, Lai L, Chen Q, Song Y, Xu S, Ma F, Wang X, Wang J, Yu H, Cao X, Wang Q. MicroRNA-494 Is required for the accumulation and functions of tumor-expanded myeloid-derived suppressor cells via targeting of PTEN. J Immunol 2012, 188(11):5500-5510. 10.4049/jimmunol.1103505, 22544933.
45. Olaru AV, Ghiaur G, Yamanaka S, Luvsanjav D, An F, Popescu I, Alexandrescu S, Allen S, Pawlik TM, Torbenson M, Georgiades C, Roberts LR, Gores GJ, Ferguson-Smith A, Almeida MI, Calin GA, Mezey E, Selaru FM. MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology 2011, 54:2089-2098. 10.1002/hep.24591, 3212606, 21809359.
46. Yamanaka S, Campbell NR, An F, Kuo SC, Potter JJ, Mezey E, Maitra A, Selaru FM. Coordinated effects of microRNA-494 induce G2/M arrest in human cholangiocarcinoma. Cell Cycle 2012, 11:2729-2738. 10.4161/cc.21105, 3409013, 22785131.
47. Ohdaira H, Sekiguchi M, Miyata K, Yoshida K. MicroRNA-494 suppresses cell proliferation and induces senescence in A549 lung cancer cells. Cell Prolif 2012, 45:32-38. 10.1111/j.1365-2184.2011.00798.x, 22151897.
48. Kim WK, Park M, Kim Y-K, Tae YK, Yang H-K, Lee JM, Kim H. MicroRNA-494 Downregulates KIT and Inhibits Gastrointestinal Stromal Tumor Cell Proliferation. Clin Cancer Res 2011, 17:7584-7594. 10.1158/1078-0432.CCR-11-0166, 22042971.
49. Romano G, Acunzo M, Garofalo M, Di Leva G, Cascione L, Zanca C, Bolon B, Condorelli G, Croce CM. MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. Proc Natl Acad Sci U S A 2012, 109:16570-16575. 10.1073/pnas.1207917109, 3478630, 23012423.
50. Ohdaira H, Sasaki T, Yoshida K. A subset of microRNAs potentially acts as a convergent hub for upstream transcription factors in cancer cells. Oncol Rep 2010, 24:1371-1381.
51. Rana S, Malinowska K, Zoller M. Exosomal tumor microRNA modulates premetastatic organ cells. Neoplasia 2013, 15:281-295. 3593151, 23479506.
52. Yamada Y, Enokida H, Kojima S, Kawakami K, Chiyomaru T, Tatarano S, Yoshino H, Kawahara K, Nishiyama K, Seki N, Nakagawa M. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci 2011, 102:522-529. 10.1111/j.1349-7006.2010.01816.x, 21166959.
53. Wang G, Mao W, Zheng S. MicroRNA-183 regulates Ezrin expression in lung cancer cells. FEBS Lett 2008, 582:3663-3668. 10.1016/j.febslet.2008.09.051, 18840437.
54. Abraham D, Jackson N, Gundara JS, Zhao J, Gill AJ, Delbridge L, Robinson BG, Sidhu SB. MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets. Clin Cancer Res 2011, 17:4772-4781. 10.1158/1078-0432.CCR-11-0242, 21622722.
55. Giricz O, Reynolds PA, Ramnauth A, Liu C, Wang T, Stead L, Childs G, Rohan T, Shapiro N, Fineberg S, Kenny PA, Loudig O. Hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity. J Pathol 2012, 226:108-119. 10.1002/path.2978, 21953071.